EcoDrugPlus

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSG00000134853
Gene: PDGFRA
Gene Synonyms: CD140A,GAS9,PDGFR2
29 APIs:
24 Enzyme and pathways 9 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSG00000113721
Gene: PDGFRB
Gene Synonyms: CD140B,JTK12,PDGFR,PDGFR1
40 APIs:
15 Enzyme and pathways 8 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSG00000100311
Gene: PDGFB
Gene Synonyms: SIS,SSV
1 APIs:
21 Enzyme and pathways 8 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 4

Ensembl ID : ENSG00000142731
Gene: PLK4
Gene Synonyms: SAK,STK18
2 APIs:
16 Enzyme and pathways 8 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSG00000143799
Gene: PARP1
Gene Synonyms: ADPRT,ARTD1,PARP,PARS,POLY-PARP,PPOL
10 APIs:
31 Enzyme and pathways 7 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSG00000129484
Gene: PARP2
Gene Synonyms: ADPRTL2,ARTD2
10 APIs:
13 Enzyme and pathways 7 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSG00000041880
Gene: PARP3
Gene Synonyms: ADPRT3,ADPRTL3,ARTD3,HPARP-3,IRT1,PADPRT-3
4 APIs:
7 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Porcupine O-Acyltransferase

Ensembl ID : ENSG00000102312
Gene: PORCN
Gene Synonyms: DHOF,MG61,POR,PORC,PPN
1 APIs:
7 Enzyme and pathways 8 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSG00000156113
Gene: KCNMA1
Gene Synonyms: KCA1.1,MSLO1,SLO
3 APIs:
12 Enzyme and pathways 8 Cross references
297 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSG00000104783
Gene: KCNN4
Gene Synonyms: HIKCA1,HKCA4,HSK4,IK,KCA3.1
2 APIs:
3 Enzyme and pathways 9 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSG00000187486
Gene: KCNJ11
Gene Synonyms: BIR,KIR6.2
13 APIs:
17 Enzyme and pathways 8 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSG00000123700
Gene: KCNJ2
Gene Synonyms: IRK1,KIR2.1,LQT7
1 APIs:
18 Enzyme and pathways 9 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).